Literature DB >> 33505125

Evaluation of Anti-hypertrophic Potential of Enicostemma littorale Blume on Isoproterenol Induced Cardiac Hypertrophy.

V A Doss1, Dharaniyambigai Kuberapandian1.   

Abstract

The main objective of this study is to evaluate the anti-hypertrophic potential of the aqueous extract of Enicostemma littorale (E. littorale) against isoproterenol induced cardiac hypertrophic rat models (male albino Wistar rats) through biochemical investigations. Aqueous extract of E. littorale known for various beneficial properties was administered (100 mg/kg, 12 days, oral) to isoproterenol (ISO) induced cardiac hypertrophic rats (low ISO-60 mg/kg, 12 days and high ISO-100 mg/kg, 12 days, subcutaneous) and were compared with group that was treated with the reference drug, Losartan (10 mg kg, administered for 12 days, oral). The anti-hypertrophic effect of E. littorale was evaluated by analysing the morphometric indices of the heart, ECG tracings, changes in blood biochemical parameters viz., serum glucose, serum total protein, serum albumin, lipid profile, cardiac specific enzymes (SGOT, SGPT and LDH) and histopathological examination of the heart tissue. The results fundamentally revealed that the plant extract efficiently ameliorated cardiac hypertrophy induced by ISO injected in experimental rats. The outcomes of biochemical investigations of this study highlighted the association between the hypertrophic β-adrenergic receptor signalling (β-AR) and the 5' AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) axis in the metabolism of cardiac fibrosis and hypertrophy. This β-AR/AMPK-PGC1α signalling stem can serve as a key target in ameliorating cardiac hypertrophy through focus on its principal regulators. To add, we also propose that the glycoside, swertiamarin present in this plant with the reported anti-fibrotic potential in liver can be further isolated and evaluated for its anti-hypertrophic potential to treat cardiac hypertrophy. © Association of Clinical Biochemists of India 2019.

Entities:  

Keywords:  Anti-hypertrophic effect; Cardiac fibrosis; Cardiac hypertrophy; Enicostemma littorale; Isoproterenol; Swertiamarin

Year:  2019        PMID: 33505125      PMCID: PMC7817753          DOI: 10.1007/s12291-019-0814-x

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  34 in total

1.  Increased susceptibility to isoproterenol-induced cardiac hypertrophy and impaired weight gain in mice lacking the histidine-rich calcium-binding protein.

Authors:  Eric J Jaehnig; Analeah B Heidt; Stephanie B Greene; Ivo Cornelissen; Brian L Black
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

2.  Cardiovascular effects of cyclosporin treatment in an experimental model.

Authors:  Paula Tavares; Flávio Reis; C A Fontes Ribeiro; Frederico Teixeira
Journal:  Rev Port Cardiol       Date:  2002-02       Impact factor: 1.374

Review 3.  PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure.

Authors:  Carles Cantó; Johan Auwerx
Journal:  Curr Opin Lipidol       Date:  2009-04       Impact factor: 4.776

4.  Fibroblast growth factor 21 protects against cardiac hypertrophy in mice.

Authors:  A Planavila; I Redondo; E Hondares; M Vinciguerra; C Munts; R Iglesias; L A Gabrielli; M Sitges; M Giralt; M van Bilsen; F Villarroya
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas' disease.

Authors:  Mariana C Waghabi; Elen M de Souza; Gabriel M de Oliveira; Michelle Keramidas; Jean-Jacques Feige; Tania C Araújo-Jorge; Sabine Bailly
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

6.  Chronic converting enzyme inhibition normalizes QT interval in aging rats.

Authors:  V J Dias da Silva; E Ferreira Neto; H C Salgado; R Fazan
Journal:  Braz J Med Biol Res       Date:  2002-09       Impact factor: 2.590

7.  Effect of isoproterenol on the metabolism of myocardial fatty acids.

Authors:  S Al Makdessi; J L Andrieu; H Herilier; G Faucon
Journal:  J Mol Cell Cardiol       Date:  1987-02       Impact factor: 5.000

8.  Antidepressant Activity of Enicostemma littorale Blume in Shp2 (Protein Tyrosine Phosphatase)-inhibited Animal Model of Depression.

Authors:  V A Doss; Dharaniyambigai Kuberapandian
Journal:  Int J Prev Med       Date:  2016-09-27

9.  Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway.

Authors:  Nouf M Al-Rasheed; Maha M Al-Oteibi; Reem Z Al-Manee; Sarah A Al-Shareef; Nawal M Al-Rasheed; Iman H Hasan; Raeesa A Mohamad; Ayman M Mahmoud
Journal:  Drug Des Devel Ther       Date:  2015-06-23       Impact factor: 4.162

10.  Inhibition of angiotensin II-induced cardiac hypertrophy and associated ventricular arrhythmias by a p21 activated kinase 1 bioactive peptide.

Authors:  Rui Wang; Yanwen Wang; Wee K Lin; Yanmin Zhang; Wei Liu; Kai Huang; Derek A Terrar; R John Solaro; Xin Wang; Yunbo Ke; Ming Lei
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.